GleamWall
中文EN

ERAS Erasca, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—

Leverage & solvency

Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$47.20M$35.90M$27.27M$23.24M$22.47M$21.17M$25.97M$26.12M
SG&A expense$12.33M$11.72M$10.65M$9.36M$10.07M$9.46M$9.66M$9.59M
Operating income-$59.52M-$47.62M-$187.91M-$32.60M-$34.55M-$38.12M-$35.63M-$35.71M
Net income-$51.33M-$44.08M-$183.44M-$29.09M-$30.61M-$33.88M-$30.97M-$32.23M
EBITDA-$58.81M-$46.90M-$187.19M-$31.86M-$33.79M-$37.34M-$34.81M-$34.88M
EPS (basic)-0.15-0.14-0.60—-0.11-0.12-0.11—
EPS (diluted)-0.15-0.14-0.60—-0.11-0.12-0.11—
Dividends declared per share0.000.000.000.000.00———
Weighted avg. shares (diluted)344.24M311.34M304.32M—283.68M283.36M283.26M—
Balance sheet
Cash & equivalents$118.96M$42.54M$47.26M$73.81M$70.23M$66.14M$70.48M$67.74M
Short-term investments$524.74M$226.20M$196.53M$202.27M$218.17M$234.52M$234.10M$230.57M
Current assets$655.19M$278.44M$253.78M$286.24M$299.93M$310.66M$314.62M$308.79M
PP&E, net$11.33M$11.92M$12.61M$13.30M$14.04M$14.82M$15.59M$16.32M
Total assets$998.94M$435.05M$461.23M$396.15M$420.40M$445.39M$471.24M$502.53M
Current liabilities$43.99M$33.57M$26.66M$28.51M$28.71M$28.15M$25.47M$31.39M
Total liabilities$82.20M$73.19M$67.71M$70.98M$72.52M$73.13M$71.74M$79.03M
Shareholders' equity$916.74M$361.87M$393.53M$325.17M$347.89M$372.26M$399.50M$423.50M
Shares outstanding350.24M312.56M310.81M284.16M283.71M283.65M283.27M283.22M
Cash flow statement
Operating cash flow-$32.74M-$27.27M-$27.38M-$21.71M-$21.66M-$20.53M-$31.55M-$24.56M
Capital expenditure$79,000$8,000$36,000$9,000$6,000$30,000$83,000$0
Free cash flow-$32.82M-$27.28M-$27.42M-$21.72M-$21.66M-$20.56M-$31.64M-$24.56M
Investing cash flow-$488.34M$19.49M-$243.83M$24.71M$25.70M$15.74M$34.27M$22.62M
Financing cash flow$597.50M$3.06M$244.66M$575,000$41,000$447,000$33,000$801,000
Depreciation & amortization$712,000$716,000$723,000$743,000$755,000$787,000$822,000$832,000
Stock-based compensation$11.93M$9.61M$8.46M$5.82M$5.96M$6.40M$6.71M$6.31M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.